Status: Not yet recruiting
Safety Study of GMDTC Injection in Participants With Solid Tumors and Cisplatin-Induced Renal Dysfunction
This trial is a multicenter, combined hydration, multiple-dose, dose-escalation phase Ib clinical study, designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of the injection product GMDTC in participants with solid tumors and cisplatin-induced mild renal impairment.
Participants needed: 60
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Guangdong Jianersheng Pharmaceutical Technology Co., Ltd.Updated: Sep 17, 2026Locations: 1
Eligibility criteria
The subject is able to understand and voluntarily sign a written Informed Consen... [+5]
Those who have participated in any other clinical trials within 4 weeks before t... [+33]